Share Name Share Symbol Market Type Share ISIN Share Description
Mediwatch LSE:MDW London Ordinary Share GB0006633738 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 5.875p 0.00p 0.00p - - - 0.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 10.1 0.1 0.1 97.9 8.28

Mediwatch (MDW) Latest News

Real-Time news about Mediwatch (London Stock Exchange): 0 recent articles
More Mediwatch News
Mediwatch Takeover Rumours

Mediwatch (MDW) Share Charts

1 Year Mediwatch Chart

1 Year Mediwatch Chart

1 Month Mediwatch Chart

1 Month Mediwatch Chart

Intraday Mediwatch Chart

Intraday Mediwatch Chart

Mediwatch (MDW) Discussions and Chat

Mediwatch (MDW) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Mediwatch trades in real-time

Mediwatch (MDW) Top Chat Posts

DateSubject
11/12/2013
21:54
dorset64: Trout, my point about being right was that I stated it was the wrong business model for MDW to be releasing experienced sales staff, in favour of taking on university graduates. You argued against me on that but in your latest posts, you then go on to state that the cost cutting (graduates instead of sales staff etc.) was unsustainable move & MDW would fail if they carried on. That to me tells me that you now agree with my previous posts and they were correct. One other point I don't really understand, and perhaps I'm being a little thick here but why are Lab paying in excess of £10m for MDW, when they have also now bought MDW's suppliers which, in turn they could had simply turned off the supply tap to MDW. If they had done this then MDW, along with it's share price would have drowned as with no supply, they would not be able to carry on with their business until a new supplier had been found. So the question is, are there other suppliers out there that could have supplied MDW and, if so how long would the authorities/approvals taken to be back in business, whereas if the answer was no/not really feasible, then why didn't Lab simply wait until MDW was a true basket case and make an offer then, for what probably would had been 10-20% of the price they are now paying. So that must mean there are other areas in the business that are worth money of which would not be hamstrung by the T-Doc supply chain.
18/11/2013
09:35
davidosh: For me this is a very interesting case study in how the market works in small caps. Firstly as someone who heavily invests in small companies I find it important to know the dynamics of those running the company and also those who make up the shareholder register as ultimately the shareholders do have a vote in situations that develop like this. Secondly I am now interested in why the share price remained so low for years if the company was ultimately going to be worth at least double that share price and clearly many of you feel much more as a multiple ! Why were some of you not buying the shares and taking a greater percentage of the company to show your confidence and block any opportunistic bidding or at least improve the ultimate bid price ? NOTE... Spot the difference at Inditherm IDM where a number of private investors bought out nearly all the institutions and weak holders at around the same share price as MDW had been at for three years and now individual investors like you and me hold about 80% of the company. Three of us hold nearly 50% so if a Laborie want to negotiate they need to take us inside on the deal and not just the directors ! Thirdly....How many regular presentations have Mediwatch done for investors to get to know the company and allow any potential to be gradually realised in the company and ensuring the share price keeps up with any potential and so preventing a bid that disappoints long term holders ? Finally...How organised are you all if so visably disappointed ? What are you going to do and do you have more than the required number to block the scheme of arrangement ? You will need MORE THAN because the nominee accounts system works against you and so many will bleat loudly here but then never get round to doing everything required to activate their voting rights or hold spread bets and cannot directly vote or worse still the nominee holder never gets in touch with shareholders and sees the recommendation by the directors as the default option and votes the opposite way to your likely intentions !! A first step may be to at least establish how many shares your dissenting group will be holding but always remember that such holders are not locked in so may sell part or all of those holdings if they get a price close to the bid and see another opportunity in the market so that percentage can be fluid and you need a strong leader in any campaign. If you want to organise yourselves then you may want to read the many action group cases that ShareSoc the individual shareholder organisation has helped over the last three years www.sharesoc.org For those who are investors in companies I feel it is important to be a member of such an organisation and it only costs £35 a year to be a full member. For the record I am not writing this as a disinterested onlooker as I do hold shares in MDW and have done for two years but as noted earlier I have a very real interest in the wider small cap market and particularly in Inditherm which I see as a much better placed company in its market opportunity.
06/11/2013
14:23
greedfear: If Laborie was to walk away I believe any dip in the share price will be very short lived, provided the company is not going to surprise us with bad numbers and/or prospects (which I do not expect to happen at all). Clearly MDW has a committed shareholder base that would gladly take up more shares at lower prices. Besides the shareholders that reported owning 1%+ I think we would be surprised about the ones holding a number of shares in the 0.5%-1% range (I'm being one of them). A lot of long termers so I'm not worried about a possible price dip. The large numbers of 1%+ (or 0.5%+) holders is very reassuring as it will not be easy for Laborie dropping a low ball offer and getting the necessary support. I do not believe for one second that current larger holders have been in this "game" to get something like 6p in the end. A double digit number seems fair and that would get my support but nothing less. Am still expecting the share price to go up very soon. Hoping for it anyway because as it currently doesn't reflect the value, it will without any doubt be used as an argument by Laborie (well you see, the market KNOWS you're about to be taking over and yet it is not even willing to pay 4.25p, so Xp seems generous [or something like that]). I feel with any day that passes the chances of a Laborie t/o [or others joining] are improving and expect the share price to improve likewise. Anyway, just my opinion (what else?), BOL holders!
23/9/2013
12:04
barrywhit: Afternoon Trout, Even if they miss targets I don't see the share price dropping may hit 2p on the bid but I think we are at the bottom with ref. share price. If we meet or exceed targets then we may see a small gain but I only see new products acquisitions and FDA approval giving the share price a real lift in the short to medium term... We have seen how the share price reacts to good news via RNS it tends to spike to allow for the disenchanted to exit.....
15/2/2013
15:23
nick2008: P1nkfish Taking your £450k profits, I'm modifying the share price calc below Nick2008 7 Feb'13 - 23:12 - 137 of 264 1 0 edit They are drastically cutting the R&D spend. This is not not just cost cutting. This says that they are nearly at the end of product development cycle. They already state that new products will be launched in march / April this year. Yesterday I posted about pay per use servicing and a touch based ultrasound and uroflowmetry system, with industry wide renown at the American Urological Association's conference for its cutting edge design and usability (See post 116 and 117) and perhaps other new ones which is being launched. So the mgt focus is shifted from product development to Sales. This has never been the case till date. They were always developing something new. Sales initiatives - JV with Genesis (thx to Life Tech being bought out) will not just increase sales but also reduce costs as their own sales reps will not be used. This increases gross margins on their sales in UK. - the new products to be launched are perhaps due to demand from existing customers and from new markets. well! for new markets, may have to get approvals, but can get larger share of wallet from existing customers So, we are talking about around £450k profits (P1nkfish assumption in post 263) With no persistent seller like the case of institutions, What sort of share price are we talking about with just £450k profits? Corporate world uses the DCF valuation to calculate the share price, but many use the 15PE formula which says "Age old standard is that PE for shares doing the same profit year in year out was 15. i.e. 15 years of dividends to get your entire stake back. 6 percent PA etc" What this means that for every million profit, the share price will jump by (1 divided by no of shares multiply by 15PE). Of course when the companies move into profits for the first time the PEs are usually higher and reaches 20-25 as per the standards. For MDW, every £0.45m profits, the share price should jump up by = 0.45 / 140 * 15 = 4.8p Well! even without profits a organisation has underlying value although perhaps low. So, the share price should be in range around 5-6p with just £0.45m profit at the end of this year. DYOR Nick
07/2/2013
23:12
nick2008: Ultimately Results says it all and white knight is awaited. I think we all are hoping for a change this year. At the same time, the Results also has a hidden message which I think should have been highlighted and perhaps made loud and clear. They are drastically cutting the R&D spend from £700k to just £200k. This is not not just cost cutting. This says that they are nearly at the end of product development cycle. They already state that new products will be launched in march / April this year. Yesterday I posted about pay per use servicing and a touch based ultrasound and uroflowmetry system, with industry wide renown at the American Urological Association's conference for its cutting edge design and usability (See post 116 and 117) and perhaps other new ones which is being launched. So the mgt focus is shifted from product development to Sales. This is never been the case till date. They were always developing something new. Sales initiatives - JV with Genesis (thx to Life Tech being bought out) will not just increase sales but also reduce costs as their own sales reps will not be used. This increases gross margins on their sales in UK. - the new products to be launched are perhaps due to demand from existing customers and from new markets. well! for new markets, may have to get approvals, but can get larger share of wallet from existing customers Just these sales efforts, lets say, yields about £50-75k profits Add the cost cutting in R&D which is £500k, so let's assume £400k So, we are talking about around £500k profits till we wait for change or white knight. With no persistent seller like the case of institutions, What sort of share price are we talking about with just £500k profits? Corporate world uses the DCF valuation to calculate the share price, but many use the 15PE formula which says "Age old standard is that PE for shares doing the same profit year in year out was 15. i.e. 15 years of dividends to get your entire stake back. 6 percent PA etc" What this means that for every million profit, the share price will jump by (1 divided by no of shares multiply by 15PE). Of course when the companies move into profits for the first time the PEs are usually higher and reaches 20-25 as per the standards. For MDW, every £0.5m profits, the share price should jump up by = 0.5 / 140 * 15 = 5.3p Well! even without profits a organisation has underlying value although perhaps low. In case, the white knight arrives sooner then we all get our extra bonus but whilst we await the change, the share price should be in range of 5-7p with just £0.5m profit at the end of this year. DYOR Nick
22/11/2012
09:02
troutisout: Morning all, Abers the MMs are in a rut, they sold too many shares at 2p or below and since then are selling much more than they are buying, they're hoping the lower bid and wider spread will secure more sellers, in doing so yesterday they left the back door open and attracted a buyer with their lower offer. Since the trading statement we have seen the bid drop to 2p on not what I would call a stampede for the door, then we had two sells that were done under the bid and the price was subsequenly dropped further. Then that was received by a lot of buying and again a couple of days later more buying. Then we had PS's buy and further buyers entered and the price moved up. This week we have seen a buyer paying 2.5p for shares and yesterday's seller. Overall it seems to be a positive reaction to negative news, was a lot of it in the price? does this herald the bottom (when negative news is broadly taken as a buying opportunity). I personally have been looking into MDW, it's markets and competitors over the past fortnight and it would seem that MDW is still being valued by it's share price rather than the Company. Let me explain a bit more, the fire sale from Amati and other Instis forced the price down to the 2p level, this had a disproportionate effect on the share price as so many shares were hitting the market, in what is an illiquid trading share. Those have been absorbed by the market now but the share price hasn't returned to previous levels. I believe this is because people are looking at last month's share price or last year's share price rather than the Company and it's real value, it's value as a company not what the MMs are prepared to buy or sell a few £,000s of shares for. MDW is appears very undervalued compared with other listed UK small medical companies, then you should see the US ones!!!!!!! Their valuations are mad and most are consuming finance with large losses, they seem to keep going with a cycle of accepting venture capital and acquisition. I haven't yet found a Medical Device Company with £10m revenues anywhere near the single figure valuation that MDW has £3.5m (one third of sales). The market is at a low, the US market has stalled you just have to look at some of the big boys quarterly earnings reports, GE Healthcare and St Jude both reporting lower sales and a drop in profits. The election was a really important factor and the market for medical devices slowed as people waited to make any decisions, the decision has now been made and Obama has retained the Presidency. This stops the uncertainty and now people can move on, there are a lot of important things going to happen, some good and some bad for medical device manufacturers, broadly the Company feel Obama's re-election will have a positive effect on them, with Obamacare bringing up to another 30m people into the net and providing quality care for these extra people will lead to more growth in Mediwatch's markets. Finally I have noted the poor statement and the following response from the market, with a new CFO could these results incorporate a bit of kitchen sinking, a chance to clear the decks and start afresh with the CFO's first full year? I know that the US situation was a real drag on US sales and that Europe and Middle East also shrunk but there was talk of delayed orders, etc and I have heard that a certain Sandy didn't help right at the end of the period either, normally a period when they are trying to get the last sales in before period end was overtaken by nature. Maybe I am being cynical but nowadays it pays to be cynical first, but we will see in a year's time how the year on year numbers look. People are guilty of looking at the share price first and not the Company when putting a value on MDW, I saw this about MDW the other day 'There would appear to be a valuation disconnect.' DYOR, Trout.
13/7/2012
15:07
dorset64: You really need to get out and get a life Trout, instead of pouncing on anyone who should dare not buy into anything if it's MDW. I take it 'very logical' was you telling posters to buy MDW over the last few years of which, in turn they too like you would have lost copious amounts of money on MDW. How many here are in profit............. very few I doubt if any. And as you mention it some 18-20 months ago the MDW share price was over 6.5p, and you were still here pumping it. So tell me where is it today...above 6.5p... no!!! Take off your rottweiler collar along with your rose tinted specs and let others discuss what they wish too without you acting like a big child all the time. Absolutely pathetic Trout
01/12/2011
21:42
masurenguy: troutisout - 27848: As can be seen MDW has outperformed the AIM All Share over this timescale More trivia which is also complete and utter rubbish ! The AIM All Share Index opened at 934 on January 4th and closed at 696 tonight. MDW opened at 3.62 on January 4th and closed at 2.125 tonight. Therefore AIM down by 25% and MDW down by 41% Trout has picked a timeframe - April to November - to try and show MDW in a more favourable comparative light. By April the MDW share price had already fallen by 31% to 2.50 since the begining of the year so the subsequently decline to 2.125 only represents 15% Meanwhile the AIM All Share had onl;y dropped by 4% to 900 since the begining of the year so the subsequent drop to todays close of 696 represented a subsequent fall of 23%. Based on this he is trying to claim that MDW has out performed AIM. Trout is just a dissembling charlatan and a proven prevaricator to boot. He is so desperate that he will distort anything to try and disguise the disasterous fall in the shareprice here and his consequential substantial losses. "One thing is important and that is MDW has not performed any worse than the group of peers and the All share index over the past few months even at it's present price, so don't believe everything that is posted and make your own judgements on the facts and not my or anyone else's opinions." Lets get down to reality. How many shareholders actually believe his BS ? How many are happy with the shareprice performance here and believe that MDW has been an outperforming investment compared to other options that they might have held instead ?
29/11/2011
13:45
masurenguy: troutisout - 27767: MDW hasn't fared badly, I know this is scant consolation but it has managed to tread water when others have lost a far lot more. LOL - talk about desperately clutching at straws. MDW has been stuck in an all time low range between 2.00p and 2.75p during the whole of that that time so it could hardly have gone much lower ! It would be far more relevant to compare the performance of MDW to the AIM All Share Index since it bottomed out at the begining of March 2009, following the autumn 2008 market crash. The AIM index closed at 377, its lowest ever level, on the 6th of March 2009. Today it is trading at 682, which represents an 81% increase almost 21 months later MDW closed at 7.625p on that date and is currently trading at 2.125p, which represents a fall of 72% over the same timeframe ! The MDW share price performance has been disasterous over the past 21 months as it has performed almost totally inversely to the AIM index.
Mediwatch share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20161209 17:32:39